XML 39 R21.htm IDEA: XBRL DOCUMENT v3.2.0.727
Collaboration and License Agreements, Takeda Pharmaceutical Company Limited (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
May. 31, 2014
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Dec. 31, 2014
License And Collaboration Agreements [Line Items]            
Deferred revenue current   $ 10,186   $ 10,186   $ 14,248
Deferred revenue non-current   12,722   $ 12,722   16,472
Takeda Pharmaceutical Company Limited [Member]            
License And Collaboration Agreements [Line Items]            
Non-refundable upfront payment $ 15,000          
Collaboration agreement date       May 2014    
License option fee   15,000   $ 15,000    
Upfront fee allocated to agreement   10,000   $ 10,000    
Expected period of development       24 months    
Recognized revenue under agreement   1,200 $ 400 $ 5,500 $ 400  
Deferred revenue   4,600   4,600   7,100
Deferred revenue current   4,600   4,600   5,000
Deferred revenue non-current   0   0   $ 2,100
Revenue Recognition, Milestone Method, Revenue Recognized       3,000    
Additional Potential Sales Milestone Payments Under Agreement   375,500   375,500    
Additional Potential Clinical And Regulatory Milestone Payments Under Agreement   93,000   93,000    
Takeda Pharmaceutical Company Limited [Member] | Research Collaboration And License Option Agreement [Member]            
License And Collaboration Agreements [Line Items]            
Upfront fee allocated to agreement   5,000   5,000    
Research and development services revenue   $ 400   $ 700